Irish Families Call for Increased Public Funding for Rare Disease Drugs

Families, clinicians, and campaigners in Ireland are calling on the government to provide more public funding for rare disease drugs ^[1].

Access to these treatments is critical because many rare disease therapies are high-cost and currently unavailable through public health channels. Without state support, patients often face insurmountable financial barriers to accessing medicines that could save or significantly improve their lives [1, 2, 4].

Approximately 300,000 people in Ireland are affected by rare diseases ^[1]. These patients navigate a complex medical landscape consisting of around 6,000 distinct rare disease conditions ^[1]. Because these conditions are uncommon, the cost of developing and administering the corresponding treatments is often high, creating a funding gap that advocacy groups are now urging the state to close [1, 2].

This push for funding in Ireland reflects a broader international struggle to balance healthcare budgets with the need for specialized medicine. Similar efforts to accelerate access to life-changing treatments have been documented in Canada and the U.S. [1, 4]. In some regions, industry initiatives and partnerships are being used to streamline the delivery of these drugs to patients who cannot afford them out of pocket [2, 3].

Clinicians in Ireland said that the current lack of public funding leaves many patients without options. The advocacy groups are seeking a systemic change in how the government allocates resources for orphan drugs, medicines developed specifically to treat rare medical conditions, to ensure that a patient's survival does not depend on their personal wealth [1, 2].